Biomedical Translation Fund (BTF)

Purpose and Program Overview

The Biomedical Translation Fund (BTF) is a major Australian Government initiative aimed at accelerating the development and commercialisation of promising biomedical discoveries. Established under the National Innovation and Science Agenda, the BTF seeks to transform early-stage biomedical research into tangible products, services, and outcomes that deliver long-term health benefits and economic growth nationally. By addressing financing and management constraints faced by emerging biomedical companies, the fund supports innovations in therapeutics, medical devices, diagnostics, and digital health services that improve patient care and health system efficiency.

With a total investment pool of approximately $500 million, comprising $250 million in Commonwealth funding matched by an equal amount from private sector investors, the BTF operates as an equity co-investment venture capital program. The fund is managed by licensed private sector fund managers who evaluate and invest in eligible Australian biomedical companies, providing both capital and commercial expertise to guide successful translation and market entry. Through this collaboration, the BTF plays a pivotal role in strengthening Australia’s biomedical innovation ecosystem and increasing the global competitiveness of its medical research sector.

Biomedical Translation Fund complements other national health research programs by supporting projects at advanced pre-clinical and early clinical stages (Phase I and Phase II), addressing the so-called ‘valleys of death’ in biomedical development where funding gaps often stall promising discoveries. It contributes to creating high-value jobs and fostering sustainable growth in the life sciences sector.

Key Grant Details

• Grant amount: Investments vary by project; no fixed amounts as it operates via venture capital equity investments
• Total funding pool: Approximately $500 million (comprised of $250 million Commonwealth and $250 million private sector investment)
• Application open and close dates: No direct application to the fund; companies engage licensed fund managers for investment consideration at any time
• Eligible industries/business types: Early-stage Australian biomedical companies developing therapeutics, medical devices, diagnostics, or digital health innovations
• Co-contributions: Matched private sector co-investment required as part of the fund’s structure
• Location/state/territory applicability: Australia-wide

Priority Sectors

The BTF focuses broadly across the biomedical sector, supporting innovations in:

• Therapeutics development (pharmaceuticals, biologics)
• Medical devices and diagnostics
• Digital health and health IT services
• Preventive, diagnostic, and treatment technologies addressing significant clinical needs

Funding Scope

• Investment stages: Targeted at biomedical projects in advanced pre-clinical, Phase I, and Phase II clinical development
• Funding categories: Equity investments supporting research translation, clinical trials, regulatory approvals, and commercialisation activities
• Project timeline: Investment horizons aligned with venture capital expectations, typically several years to market entry

Grant Amount in Total

• The total fund size is $500 million, delivered through three licensed private sector fund managers responsible for investment decisions.

Eligibility Criteria

• Australian companies engaged in biomedical discoveries within the targeted development stages
• Demonstrated potential for commercial success and health impact
• Ability to leverage private investment alongside public funding
• Commitment to building scalable biotech or medtech enterprises
• Compliance with regulatory and governance standards relevant to biomedical development

Eligible Activities and Expenses

• Translational research and development beyond initial discovery
• Proof of concept studies and validation
• Early clinical trial activities (Phase I/II)
• Regulatory and compliance efforts
• Commercial development services and infrastructure

Assessment Process

• Investment decisions are made by licensed fund managers based on commercial viability, innovation potential, and impact
• Fund managers conduct due diligence, including scientific, clinical, commercial, and financial assessments
• Applicants engage directly with fund managers for proposal evaluation and investment terms

Recent Program Updates

• The fund is currently closed to new fund managers, but companies can approach existing licensed managers to seek investment
• Notable investors include CSL Limited and significant Australian superannuation funds, providing both capital and expertise
• The fund continues to evolve as a cornerstone for biomedical translation in Australia, supporting sector growth and commercialisation pathways

Application Tips

• Engage with licensed Biomedical Translation Fund managers proactively to discuss investment potential
• Prepare detailed commercial and scientific documentation demonstrating development progress and market opportunity
• Highlight partnerships, intellectual property position, and regulatory strategies
• Clarify funding requirements and co-investment arrangements
• Seek professional advisory support to align proposals with investor expectations

Where to Get Help for Biomedical Translation Fund

Consider consulting with professional grant specialists such as Pattens Group for guidance on eligibility and strategies for introducing your project to BTF fund managers. Further information and contacts can be accessed through the Australian Government’s business.gov.au portal and biomedical innovation networks.